Retreatment and AETHERA Training Quiz

True or False: Patients who experience AEs during their last treatment with brentuximab vedotin were allowed to start at the last dose used in the retreatment study
True
False
The key response results for the retreatment study are
ORR (CR+PR) was 88% for HL patients and 60% for sALCL with a median duration of response of 12.3 months for sALCL and 9.2 months for HL
ORR (CR+PR) was 60% for HL patients and 88% for sALCL with a median duration of response of 9.2 months for sALCL and 12.3 months for HL
ORR (CR+PR) was 75% for HL patients and 60% for sALCL with a median duration of response of 10 months for sALCL and 7 months for HL
O ORR (CR+PR) was 60% for HL patients and 75% for sALCL with a median duration of response of months 7 months for sALCL and 10 months for HL
The efficacy evaluable population for the retreatment study included:
20 HL and 8 sALCL
8 HL and 20 sALCL
10 HL and 18 sALCL
18 sALCL and 10 HL
{"name":"Retreatment and AETHERA Training Quiz", "url":"https://www.quiz-maker.com/QPREVIEW","txt":"True or False: Patients who experience AEs during their last treatment with brentuximab vedotin were allowed to start at the last dose used in the retreatment study, The key response results for the retreatment study are, The efficacy evaluable population for the retreatment study included:","img":"https://www.quiz-maker.com/3012/images/ogquiz.png"}
Powered by: Quiz Maker